C. Rabascio

发表

Circulating endothelial cell number and viability are reduced by exposure to high altitude.

F. Bertolini, F. Peccatori, P. Mancuso, 2008, Endothelium : journal of endothelial cell research.

Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer

G. Martinelli, F. Bertolini, F. Peccatori, 2004, Clinical Cancer Research.

In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue.

S. Minucci, G. Pruneri, G. Martinelli, 2002, Experimental hematology.

Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.

D. Radice, G. Martinelli, L. Rigacci, 2010, Leukemia research.

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.

D. Radice, G. Pruneri, G. Martinelli, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses

J. Heymach, C. Tacchetti, F. Bertolini, 2009, Clinical Cancer Research.

Circulating perivascular progenitors: A target of PDGFR inhibition

F. Bertolini, I. Martín-Padura, P. Mancuso, 2011, International journal of cancer.

Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strains

G. Pruneri, F. Bertolini, L. Shultz, 2008, International journal of cancer.

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.

R. Zini, S. Ferrari, M. Baccarani, 2008, Blood.

A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer.

G. Martinelli, F. Bertolini, P. Ferrucci, 2007, International journal of oncology.

Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.

G. Martinelli, F. Bertolini, F. Peccatori, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cytometry and Molecular and Ultrastructural Analyses Circulating Endothelial Cells and Progenitors : Flow Validation of a Standardized Method for Enumerating

J. Heymach, F. Bertolini, A. Zurita, 2008 .

Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine.

A. Goldhirsch, G. Viale, C. Criscitiello, 2015, Breast.

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

D. Radice, G. Pruneri, G. Martinelli, 2010, Leukemia & lymphoma.

Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis

D. Radice, G. Pruneri, G. Martinelli, 2007, Leukemia & lymphoma.

Who should be really considered as a poor mobilizer in the plerixafor era?

D. Radice, G. Martinelli, C. Rabascio, 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease.

G. Martinelli, F. Peccatori, G. Cetto, 2012, International immunology.

Antibodies against human cytomegalovirus late protein UL 94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease

G. Martinelli, F. Peccatori, G. Cetto, 2012 .

Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma – a case report

G. Pruneri, M. Faretta, F. Bertolini, 2015, Scientific reports.

Abstract

C. Rabascio, L. Saronni, F. Franchi, 2007 .

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat

A. Goldhirsch, G. Pruneri, G. Martinelli, 2004, European journal of haematology.

Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies

F. Bertolini, C. Rabascio, 2010, Cancers.

A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.

D. Radice, C. Rabascio, D. Laszlo, 2020, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression.

F. Bertolini, A. Manconi, F. Reggiani, 2017, Cancer research.

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab

A. Goldhirsch, Y. Shaked, F. Bertolini, 2009, Clinical Cancer Research.

CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.

Giovanni Martinelli, Giancarlo Pruneri, G. Pruneri, 2002, Cancer research.

Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.

G. Martinelli, G. Pinotti, L. Rigacci, 2007 .

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.

G. Martinelli, L. Rigacci, A. Pinto, 2011, Clinical lymphoma, myeloma & leukemia.

Is there a role for ‘modified VAD’ in the treatment of multiple myeloma?

G. Pruneri, G. Martinelli, P. Mancuso, 2009, Ecancermedicalscience.